Femasys Inc.

NasdaqCM FEMY

Femasys Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 363.82 K

Femasys Inc. Gross Profit is USD 363.82 K for the Trailing 12 Months (TTM) ending September 30, 2024, a -48.46% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Femasys Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 705.87 K, a -12.37% change year over year.
Femasys Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 805.51 K.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: FEMY

Femasys Inc.

CEO	Ms. Kathy Lee-Sepsick M.B.A.
IPO Date	June 18, 2021
Location	United States
Headquarters	3950 Johns Creek Court
Employees	32
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Clinical Trials Cosmetics Medical Instruments Personal Care Pharmaceuticals

Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Key trends

Past 5 years